Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00229736 | A Study of AAV-hAADC-2 in Subjects With Parkinson's Disease | PHASE1 | COMPLETED | 10 | — | — | Nov 1, 2004 | Mar 1, 2013 | Dec 4, 2013 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| AAV-hAADC-2 (9x10^10 vector genomes) | EXPERIMENTAL | - |
| AAV-hAADC-2 (3x10^11 vector genomes) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| AAV-hAADC-2 | GENETIC | 9 x 10\^10 vector genomes (vg) of AAV-hAADC-2 in a single dose of 200 µL bilaterally infused over 4 striatal targets |
Inclusion Criteria: * Documented informed consent. * Diagnosis of idiopathic Parkinson's disease (two of four cardinal features - tremor, bradykinesia, rigidity and postural instability - plus early dopaminergic responsiveness of symptoms and absence of any cardinal signs of more widespread neurolo...